Evaluate the Immunogenicity of a Novel Glucagon Formulation
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study provides information on immunogenicity of Nasal Glucagon (AMG504-1) with regards
to the potential development of treatment-emergent anti-glucagon antibodies.